Oxygenta Pharmaceutical FY26: A ₹113 Cr Topline, a ₹42 Cr Hole Where the Net Worth Should Be

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Oxygenta Pharmaceutical closed FY26 with revenue of ₹112.98 crore, up 3.37% from ₹109.3 crore the year before — and a net loss of ₹17.57 crore, the deepest in its recorded history. Sales nearly tripled over three years on a 54% three-year CAGR, yet profit went the other way, with the bottom line worsening from a ₹9.68 crore loss in FY25.

The arithmetic that frames everything: net worth sits at negative ₹42.69 crore, book value at negative ₹11.5 per share. Borrowings climbed from ₹62.23 crore to ₹109.57 crore in twelve months while cash on the books is ₹2.15 crore. ROCE is -33.4%.

Mid-year, the ownership changed hands — Virupaksha Organics acquired a 56.5% stake in June 2025, making Oxygenta a subsidiary. In October, a regulator suspended the manufacturing license for seven days. The auditor, for its part, signed off with an unmodified opinion.

So the company is selling more pharmaceutical intermediates than ever and losing more money than ever, simultaneously. The teaser worth holding onto: where does a topline grow this fast while the equity goes underwater?

2. Introduction

Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures bulk drugs and APIs, including pharmaceutical preparations and organic fine chemicals. It wore a different name for most of that history — S.S. Organics Ltd — until the change took effect on 10 February 2022.

The defining event of FY26 happened off the balance sheet first. In June 2025, Virupaksha Organics Limited acquired a 55.37% stake (later 56.5%), and Oxygenta became a subsidiary of a larger organics house. The acquisition triggered a near-total turnover of the board and the reclassification of the old promoter group to public.

The churn continued all year. In August 2025, the MD and CFO resigned alongside an independent director, effective 18 August. A new CFO came in November. By May 2026, when the board met to approve the FY26 audited results, it also appointed two additional directors and a fresh internal auditor.

One more thread runs underneath: in October 2025, the Drug Control Administration suspended Oxygenta’s manufacturing license for seven days over violations of the Drugs and Cosmetics Act, a matter the company pegged at roughly ₹20 lakh.

A pharma company changed owners, changed its board twice, lost its license for a week, and grew revenue. All four happened in the same twelve months.

3. Business Model: WTF Do They Even Do?

Oxygenta makes the unglamorous middle of the medicine cabinet. The product list runs to Losartan potassium intermediate, Gabapentin intermediate, and active ingredients for antihypertensive, anti-cancer, antiulcer, antiretroviral, and antiviral drugs. These are intermediates and APIs — the chemistry that goes into the pill, not the branded box on the shelf.

The entire operation sits in one reporting segment: manufacturing of pharmaceutical products. There’s no diversification to hide behind and no second business line to carry a weak quarter. When the chemistry sells, revenue moves; when a regulator pauses the plant, there is nothing else running.

The model’s tell is in the cost line. Of ₹135.45 crore in total FY26 expenses, raw material consumed was ₹110.34 crore — about 98% of revenue spent on materials alone before a single rupee of labour, power, finance, or depreciation. That is the economics of a price-taker buying chemicals and selling slightly-more-finished chemicals into a market that decides the spread.

Installed bulk-drug capacity has stood at 320 MTPA. Employee headcount has hovered around 175. This is a small, single-site, materials-heavy manufacturer where the gross margin is the whole story — and the gross margin barely exists.

Does a business that spends 98 paise of every revenue rupee on raw material have a margin problem, or a model problem?

4. Financials Overview

Figures are consolidated, in ₹ crore. (The audited statement is standalone; the Screener data carries it forward as the company’s reported set.)

The March quarter is the cleanest line in the file: operating profit turned positive at ₹0.12 crore — the first non-negative operating quarter in the recorded run — and the loss narrowed sharply against both the prior year and the prior quarter. Revenue was flat YoY but jumped